Supplementary Table S2 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
收藏数据链接：
官方服务：
资源简介：
Representativeness of study participants
创建时间：
2025-02-17
